Steven M. Rowe, MD, M.S.P.H.

Professor
University of Alabama at Birmingham

Poster(s):

• (15) Promise: Glucose excursion & insulin secretion following 12-18 months of highly effective modulator therapy
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (113) Development and Characterization of Pulmonary Disease in G551D Ferret Model on Chest CT Imaging
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (137) Tobacco smoke exposure reduces the clinical efficacy of ivacaftor: Results from the G551D observational trial (GOAL)
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (154) In Vitro Responses OF F508DEL Human Nasal Epithelial Cells Correlate to Clinical Improvement to ELEXACAFTOR/TEZACAFTOR/IVACAFTOR
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (155) Longitudinal Improvements in Clinical and Functional Outcomes following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (173) Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in children with cystic fibrosis: The Pediatric PROMISE study
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (410) Hypoxia-induced CFTR dysfunction is a universal mechanism underlying reduced mucociliary transport in sinusitis
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (572) Changes in total IgE levels and fungal acquisition in People with CF before and after Elexacaftor/Tezacaftor/Ivacaftor Initiation
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (610) Evaluating the mechanism of amino acid insertion upon readthrough of CFTR nonsense mutations
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (613) Understanding synergy in nonsense suppression therapy for CFTR nonsense mutations
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (645) A Novel eRF1 Degrader Induces Translational Readthrough of CFTR Nonsense Mutations to Therapeutically Relevant Levels in Combination with Aminoglycosides
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (661) The PDE4 Inhibitor Apremilast Enhances Benefits of CFTR Modulators in vitro and in vivo
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (691) Synthetic aminoglycoside ELX-02 induces readthrough of CFTR-G550X producing super-functional protein that can be further enhanced by CFTR correctors
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET